N-myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers
G. A. Lueg, M. Faronato, A. Gorelik, A. Goya Grocin, E. Caamano-Gutierrez, F. Falciani, R. Solari, R. Carr, A. S. Bell, E. Bartlett, J. A. Hutton, M. Llorian-Sopena, P. Chakravarty, B. Brzezicha, M. Janz, M. J. Garnett, D. P. Calado, E. W. Tate
Abstract
Human N-myristoyltransferases (NMTs) catalyze N-terminal protein myristoylation, a modification regulating membrane trafficking and interactions of >100 proteins. NMT is a promising target in cancer, but a mechanistic rationale for targeted therapy remains poorly defined. Here, large-scale cancer cell line screens against a panel of NMT inhibitors (NMTi) were combined with systems-level analyses to reveal that NMTi is synthetic lethal with deregulated MYC. Synthetic lethality is mediated by post-transcriptional failure in mitochondrial respiratory complex I protein synthesis concurrent with loss of myristoylation and degradation of complex I assembly factor NDUFAF4, followed by mitochondrial dysfunction specifically in MYC-deregulated cancer cells. NMTi eliminated MYC-deregulated tumors in vivo without overt toxicity, providing a new paradigm in which targeting a constitutive co-translational protein modification is synthetically lethal in MYC-deregulated cancers. One-sentence summaryN-myristoyltransferase inhibition leads to post-transcriptional complex I failure and cell death in MYC-deregulated cancers
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cumate-inducible models of MYC-driven neuroblastoma identify mitoribosomal synthetic lethality as a precision oncology vulnerability in MYC(N)-amplified tumors
Adela Kubistova, I. R. Horak, … Jan Skoda·bioRxiv·Oct 1, 2026
- Proteome-wide probing of the dual NMT-dependent myristoylation tradeoff unveils potent, mechanism-based suicide inhibitors
F. Riviere, C. Dian, … T. Meinnel·bioRxiv·Jun 22, 2021
- Nitroxoline-O-protected derivatives inhibit MetAP2 and activate ATF4 through mTORC1 to inhibit cancer cell growth
Michael J. Williams, Conor T. Ronayne, … Venkatram R. Mereddy·Bioorganic & Medicinal Chemistry LettersPeer-reviewed·Mar 28, 2026
- Identification of MYC synthetic lethal genes and networks
Timothy D. Martin, Mei Yuk Choi, … Stephen Joseph Elledge·bioRxiv·Apr 25, 2024
- Complex I Drives Glutamine-Dependent TCA Cycle to Support Viability of MYChigh Breast Cancer Cells
Johanna M. Anttila, Mariel Savelius, … Juha T. Klefström·bioRxiv·May 27, 2025
- MYC amplifies mitotic perturbations elicited by LXY18 to enable synthetic lethality
D. Yang, J. Kalashova, … Q. Shi·bioRxiv·Nov 7, 2023